|
Sigma-Aldrich is pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds. The collection, produced in collaboration with TimTec Inc., is the result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. The MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical diversity while maintaining drug-likeness.
Superior structural diversity - Distinct drug-like properties
MyriaScreen was created by combining medicinal chemistry expertise and decades of experience in compound acquisition from diverse sources. TimTec’s proprietary software was used to filter a pool of over 300,000 TimTec and Sigma-Aldrich compounds on the basis of diversity. Additional filters were set to consider MW (>225 and <600), cLogP, H-acceptor, H-donors, and rotatable bonds. Medicinal chemistry specialists refined the selection with great personal attention to remove compounds that were overly represented or not well suited for medicinal chemistry follow-up. MyriaScreen is rich in chemotypes and a valuable source of screening compounds for lead discovery.
Ready-to-use format - High purity - Efficient re-supply
MyriaScreen is pre-plated for your convenience, 0.5 mg in 250 µL of DMSO per well. The compounds have an average purity > 95% with nothing below 90%. Should you require more material for follow-up, re-supply or re-synthesis is available. Although MyriaScreen is designed for use as a complete set, there are two alternative options to fit your purchasing needs. Compounds can be purchased as individual plates or cherry-picked and plated on a custom basis.
Click here for more information or to request a MyriaScreen Diversity Collection SDFile.
MyriaScreen was produced in collaboration with  .
|
